Not a bloody soul of sellers around. The market is clearly in favour of management rejecting ACADIA's offer IMHO.
For me, the risk/reward ratio is compelling here for sp to rise in the months ahead before the trading halt for a new upgraded decent offer from ACADIA as I believe they will not want to see a 3rd party to come and scoop up NEU.
On a side note, I think it is better for NEU to split up ROW deal into 2 geographies: Europe and Asia Pacific+ Middle East (Australia, New Zealand, Japan, Korea, Hong Kong, Singapore, Indonesia, China, India...The middle class population (wealthy people) in these countries easily exceeded North America population. I believe management is thinking and planning 2 geographic markets as above to maximize shareholders' values because it does make sense. Asia Pacific+ MIddle East to a Japanese pharma and Europe to a European giant.
Ann: Plans for Phase 3 trial in Rett syndrome, page-86
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |